Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal
US drugmaker adjusts strategy of pursuing deals to replenish drug pipeline
European health officials have advocated portfolio diversity to help fight different variants
Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots
Acquisition price tag will leave investors feeling queasy
US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity
Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs
US drugmaker expects revenues of between $67bn and $71bn this year, down from a record
Officials row with Pfizer over price as villages struggle to obtain antiviral medication
Demand for antiviral treatment has rocketed after jump in infections following Beijing policy U-turn
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
Pfizer’s antiviral ‘more coveted than Moutai’ as authorities restrict imports despite virus wave
US judge dismisses almost 2,500 lawsuits alleging links between heartburn medication and cancer
Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn on Tuesday
US drugmaker’s coronavirus vaccine has almost doubled in price since its launch in 2020
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs to fight the Covid-19 pandemic
FDA clears jabs despite lack of human trials in effort to curb winter wave of Covid infections
US biotech claims rival Covid vaccine makers infringed patents underpinning jabs developed to combat the pandemic
US pharma group says RSV vaccine is 86% effective at preventing severe disease
Vaccine targeting BA.4/BA.5 could become first shot to win green light without human trials
US drugmaker and French partner begin late-stage trial with 14% of global population showing evidence of infection
Big Pharma group is using cash pile from sales of Covid-19 vaccines to replenish drug pipeline
Paxlovid dominates antiviral treatment market but weak demand could cause supply glut, data group says
US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill
